indicates that although rituximab plus cyclophosphamide followed by belimumab showed potential benefits, it did not reach statistical significance for the primary efficacy endpoint [ 14 ].
← all excerpts
Navigating Lupus Nephritis: A Comprehensive Review of the Current Treatment Trends.
1
—
—